Q1 Earnings Forecast for ProKidney Issued By HC Wainwright

ProKidney Corp. (NASDAQ:PROK) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for ProKidney in a research note issued on Thursday, March 19th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.12) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for ProKidney’s FY2030 earnings at $0.17 EPS.

PROK has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProKidney in a research note on Thursday, January 22nd. Jefferies Financial Group upgraded ProKidney to a “strong-buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, ProKidney has an average rating of “Moderate Buy” and a consensus price target of $7.40.

ProKidney Trading Down 1.0%

PROK stock opened at $1.93 on Friday. The stock has a market cap of $580.60 million, a P/E ratio of -3.71 and a beta of 1.75. The stock’s fifty day simple moving average is $2.15 and its two-hundred day simple moving average is $2.42. ProKidney has a 1-year low of $0.46 and a 1-year high of $7.13.

ProKidney (NASDAQ:PROK) last released its quarterly earnings results on Wednesday, March 18th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.00 million.

Institutional Trading of ProKidney

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC bought a new position in shares of ProKidney during the 3rd quarter valued at about $4,734,000. Artia Global Partners LP purchased a new stake in ProKidney during the 4th quarter valued at $4,118,000. JPMorgan Chase & Co. boosted its position in ProKidney by 3,024.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company’s stock valued at $988,000 after buying an additional 1,615,243 shares during the period. Renaissance Technologies LLC raised its position in ProKidney by 578.6% during the 4th quarter. Renaissance Technologies LLC now owns 895,705 shares of the company’s stock valued at $2,006,000 after purchasing an additional 763,705 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in ProKidney during the 2nd quarter valued at $350,000. Hedge funds and other institutional investors own 51.59% of the company’s stock.

ProKidney Company Profile

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.